Navidea reaches into Taiwan; Guided Therapeutics shuffles its C-suite;

@FierceMedDev: BD trades $40M for diagnostics partner Alverix. More | Follow @FierceMedDev

@MichaelGFierce: How a single nanoparticle delivers two drugs separately to kill cancer cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: The FDA warns Abbott's faulty blood glucose test strips could lead to serious injury or death. Story | Follow @GalenMoore

> Navidea Biopharmaceuticals ($NAVB) has signed a deal to get Lymphoseek, its diagnostic aid, distributed in Taiwan. More

> Diagnostics outfit Guided Therapeutics has replaced CEO Mark Faupel with Gene Cartwright, who was formerly the chief of Omnyx, a Joint Venture between GE Healthcare ($GE) and the University of Pittsburgh Medical Center. Faupel will stay on as chief scientific officer. News

> The 2.3% medical device tax discourages innovation and is antithetical to the rest of the Affordable Care Act, former Congressional Budget Office Director Douglas Holtz-Eakin writes in The Hill. Column

> MedShape is touting positive data from the soft launch of its DynaNail bone fusion system in 100 allograft patients. Announcement

Biotech News

@FierceBiotech: Texas' Bellicum gets $15M to expand work on gene 'switch' tech. More | Follow @FierceBiotech

@JohnCFierce: In search for success, R&D teams are overcrowding small drug franchises. Story | Follow @JohnCFierce

@DamianFierce: Friendly reminder that there were 27 drugs approved last year and we wrote, like, 1,000 words on each. Report | Follow @DamianFierce

@EmilyMFierce: Alcohol-addicted rats treated with optogenetics stop drinking. More from FierceBiotech Research | Follow @EmilyMFierce

> Epizyme shares rocket up on news of $29M milestone awards. More

> Neurocrine shares soar with a promising second take on a PhIIb drug. Story

> Lilly is carving up to $1B out of its struggling R&D division. News

Pharma News

@FiercePharma: Move over, BigPharma. Valeant's CEO plans to elbow his way in. More | Follow @FiercePharma

@EricPFierce: China clears vaccinemakers in deaths then shuts some down. Story | Follow @EricPFierce

@CarlyHFierce: Hi-Tech Pharmacal CEO to reap almost $85M from its sale to Akorn. Article | Follow @CarlyHFierce

> Just as hep C star Sovaldi makes its debut, Gilead commercial chief says he'll retire. More

> Lilly admits 2014 sales won't hit $20B, but sticks to $3B profits target. News

Biotech Research News

> Cancer Research UK will repurpose an AstraZeneca asthma drug for kidney cancer. More

> 6 U.S. institutions receive $540M in cancer research funds. Story

> Astellas, ClearPath team up to develop vaccines for infectious diseases. Article

> Gene defect that blocks insulin release in mice may cause Type 2 diabetes. News

> Alcohol-addicted rats treated with optogenetics stop drinking. Report

> Discovery of immune boosters' role in TB control could help develop new therapeutics. Item

Pharma Manufacturing News

> $1B deal pushes GE further into biologics manufacturing. More

> Pall moves into single-use bioreactors with deal to buy ATMI LifeSciences. Article

> Chinese heparin maker Hepalink buying U.S.-based SPL. Story

> China clears vaccine makers in deaths then shuts some down. News

> EMA makes inspection reports public. Item

> Baxter issues another recall after particulate found in products. Report

 

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.